Year: 2026 | Month: June | Volume: 16 | Issue: 6 | Pages: 282-290
DOI: https://doi.org/10.52403/ijhsr.20260631
Real-World Effectiveness and Safety of Telmisartan-Amlodipine Combination Therapy in Patients with Hypertension (Right Start Study)
Suresh V. Patted1, Vikranth Reddy2, Bhagyashree A. Mohod*3, Mayur M. Mayabhate3, Akhilesh D. Sharma
1Professor & Head, Department of Cardiology, Jawaharlal Nehru Medical College (JNMC), Belagavi, Karnataka, India
2Clinical Director & Senior Consultant – Nephrology, CARE Hospitals, Banjara Hills, Hyderabad, Telangana, India
3Medical Affairs Department, Alkem Laboratories Ltd., Mumbai, Maharashtra, India
Corresponding Author: Dr. Bhagyashree A. Mohod
ABSTRACT
Background: Hypertension remains a major contributor to cardiovascular morbidity and mortality, and achieving optimal blood pressure (BP) control in routine clinical practice remains challenging. Single-pill combinations (SPCs) comprising agents with complementary mechanisms of action are recommended by contemporary guidelines to improve BP control and treatment adherence. This study evaluated the effectiveness and safety of telmisartan–amlodipine SPC therapy in patients with hypertension managed in routine clinical practice in India.
Methods: This Study was a retrospective, multicenter, observational study conducted across tertiary care centers in India. Adult patients (≥18 years) with hypertension who received telmisartan–amlodipine SPC therapy for at least 3 months and had documented baseline and follow-up BP measurements were included. The primary outcome was change in systolic BP (SBP) and diastolic BP (DBP) from baseline to 3 months. Secondary outcomes included dose-wise effectiveness and incidence of adverse events (AEs).
Results: A total of 2,497 patients were included in the analysis; 61.9% were male, and the mean age was 56.95±11.20 years. The most frequently prescribed SPC was telmisartan/amlodipine 40/5 mg (81.2%). Mean SBP decreased significantly from 160.93 ± 18 mmHg at baseline to 135.82±14 mmHg at 3 months, corresponding to a mean reduction of 25.11 mmHg (15.6%; p<0.001). Mean DBP decreased from 106.86 ± 10 mmHg to 94.79 ± 8 mmHg, representing a mean reduction of 12.06 mmHg (11.3%; p<0.001). Significant BP reductions were observed across all dose groups (p<0.001). Adverse events were reported in 14 patients (0.56%).
Conclusion: In this large real-world cohort, telmisartan–amlodipine SPC therapy was associated with substantial reductions in both SBP and DBP across all evaluated dose strengths and demonstrated excellent tolerability. These findings support the effectiveness and safety of telmisartan–amlodipine SPC therapy for hypertension management in routine clinical practice.
Key words: Hypertension, Telmisartan, Amlodipine, systolic blood pressure, diastolic blood pressure.